England Archives -

In draft guidance, NICE has said it cannot recommend Gilead Sciences’ Trodelvy in triple-negative breast cancer (TNBC), setting

NICE verdict on Trodelvy threatens unequal access to drug in UK

https://pharmaphorum.com/news/nice-verdict-on-trodelvy-threatens-unequal-access-to-drug-in-uk/

New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines

How does HTA for orphan drugs differ across Europe?

https://pharmaphorum.com/views-analysis-market-access/how-does-hta-for-orphan-drugs-differ-across-europe/

Hundreds of thousands of people in England are at risk of dependency on prescription medicines like opioid painkillers,

England is risking its own opioid epidemic, says PHE

https://pharmaphorum.com/news/england-is-risking-its-own-opioid-epidemic-says-phe/

NHS England is no longer the new kid on the block, taking up its role in 2013. In

NHS England gets commercial

https://pharmaphorum.com/digital/nhs-england-gets-commercial/

No-one can miss the ongoing saga that is the UK’s exit from the European Union (EU). The uncertainties

The shadow of Brexit on speed of access

https://pharmaphorum.com/views-analysis-market-access/the-shadow-of-brexit-on-speed-of-access/

On July 29th 2016, the new process in England for cancer drugs seeking license went live – changing

The new CDF – Navigating Cancer Drug Access in England

https://pharmaphorum.com/partner-content-oncology/new-cdf-navigating-cancer-drug-access-england/

With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what

Available on-demand: The Price is Right? – Delivering UK access for niche patient populations

https://pharmaphorum.com/debates-insight-market-access/live-webinar-the-price-is-right-uk-niche-market-access/

England